TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07160179: Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of ABBV-6628 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Sponsor: AbbVie · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 66 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$4,882,060

Rescue Site Savings

+$3,217,080

Unlock Full NCT07160179 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07160179 Rescue Dossier →